SCHEDULE: Kezar Life Sciences: Tang Capital Backs Aurinia Merger

Tang Capital Management and related entities have agreed to tender their 9.0% stake in Kezar Life Sciences in support of the merger with Aurinia Pharmaceuticals, rescinding a prior acquisition proposal.

Summary

• Tang Capital Management, Kevin Tang, and affiliated entities (the "Reporting Persons") beneficially own 664,314 shares of Kezar Life Sciences, Inc. Common Stock, representing 9.0% of the outstanding shares.
• The Reporting Persons entered into a Tender and Support Agreement on March 30, 2026, in connection with a Merger Agreement between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals, Inc.
• Under this agreement, the Reporting Persons committed to tender all their shares, subject to certain exceptions, and agreed to restrictions on their ability to take actions regarding Kezar Life Sciences and their shares.
• Concentra Biosciences, LLC, controlled by Tang Capital, has rescinded its previous proposal to acquire 100% of Kezar Life Sciences, Inc., which was originally made on October 8, 2024.
• The percentage of ownership is based on 7,371,527 shares of Common Stock outstanding as of March 23, 2026, as reported in Kezar's Annual Report on Form 10-K filed on March 27, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it confirms significant shareholder support for the merger, reducing uncertainty around its completion. The rescission of the prior bid streamlines the process.

Positives

• The Reporting Persons, holding a significant 9.0% stake, have formally agreed to support the merger with Aurinia Pharmaceuticals by tendering their shares, indicating strong shareholder alignment for the transaction.

Negatives

• Concentra Biosciences, LLC, an entity controlled by Tang Capital, has rescinded its prior acquisition proposal for 100% of Kezar Life Sciences, removing a potential alternative path for the company.

Risks

• The tender and support agreement is subject to certain exceptions and the valid termination of the Merger Agreement, implying a risk that the merger might not close.

Future Outlook

The filing indicates a clear path towards the acquisition of Kezar Life Sciences by Aurinia Pharmaceuticals, with a significant shareholder group committing to tender their shares. The rescission of a prior acquisition proposal by Concentra Biosciences removes a potential alternative, solidifying the current merger as the primary strategic direction.

Industry Context

StockSavvy.ai notes that this development reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger players like Aurinia Pharmaceuticals seek to acquire promising assets or pipelines from smaller companies like Kezar Life Sciences. Shareholder support, especially from significant holders like Tang Capital, is crucial for successful merger completion and often signals confidence in the proposed transaction terms.

Stakeholder Impact

• Shareholders: The agreement to tender shares by a significant holder (Tang Capital) increases the likelihood of the merger's successful completion, potentially providing liquidity and a defined exit price for other shareholders.
• Management/Employees: The merger will likely lead to integration efforts and potential changes in management structure or employment, though not explicitly detailed in this filing.

Next Steps

• Tendering of Subject Shares by Reporting Persons as per the Tender and Support Agreement.
• Completion of the merger between Kezar Life Sciences, Inc. and Aurinia Pharmaceuticals, Inc.

Key Dates

Recommendation

The filing confirms a significant shareholder's commitment to the merger, which is a positive step towards its completion. However, the stock is likely trading close to the merger consideration, limiting significant upside. A 'hold' recommendation is appropriate for investors awaiting the merger's finalization, as the primary event driving value is the acquisition itself, not independent operational performance.

Keywords

Kezar Life Sciences, Aurinia Pharmaceuticals, Merger Agreement, Tender Offer, Schedule 13D, Tang Capital Management, Shareholder Support, Biotechnology, Pharmaceuticals, Acquisition